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Heritability of obesity is substantial and recent meta-analyses of genome-wide association studies (GWASs)
have been successful in detecting several robustly associated genomic regions for obesity using single-
nucleotide polymorphisms (SNPs). However, taken together, the SNPs explain only a small proportion of
the overall heritability. Copy number variations (CNVs) might contribute to the ‘missing heritability’. We
searched genome-wide for association between common CNVs and early-onset extreme obesity. Four hun-
dred and twenty-four case-parents obesity trios and an independent sample of 453 extremely obese children
and adolescents and 435 normal-weight and lean adult controls were genotyped by the Affymetrix Genome-
Wide Human SNP Array 6.0. We detected 20 common copy number variable regions (CNVRs) which were
associated with obesity. The most promising CNVRs were followed-up in an independent sample of 365 obe-
sity trios, conﬁrming the association for two candidate CNVRs. We identiﬁed a common CNVR exclusively
covering the three olfactory receptor genes OR4P4, OR4S2 and OR4C6 to be associated with obesity (com-
bined P-value 5 0.015 in a total of 789 families; odds ratio for the obesity effect allele 5 1.19; 95% conﬁdence
interval 5 1.016–1.394). We also replicated two common deletions (near NEGR1 and at chromosome
10q11.22) that have previously been reported to be associated with body weight. Additionally, we support
a rare CNV on chromosome 16 that has recently been reported by two independent groups. However, rare
CNVs had not been the focus of our study. We conclude that common CNVs are unlikely to contribute sub-
stantially to the genetic basis of early-onset extreme obesity.
INTRODUCTION
Obesity is a heritable complex trait (1,2). Genome-wide
association studies (GWASs) led to the identiﬁcation of
various common single-nucleotide polymorphisms (SNPs)
for human obesity (3–8). Although most of the results of
GWASs have been highly reproducible, they explain only a
minor fraction of the variance of body mass index (BMI)
when compared with the total expected heritability of BMI
[ 50%, (9)]. Hence, a substantial ‘missing heritability’ (10)
becomes obvious, which might in part be explained by copy
number variants (CNVs). CNVs are by deﬁnition chromoso-
mal regions with sizes of 1 kb to several megabases (Mb)
being interindividually present in variable numbers. At a
genome-wide level, thousands of CNVs have already been
identiﬁed. Owing to resolution of the current technology,
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Advance Access published on December 2, 2010most of these CNVs are .5k b( 11). The database of Genomic
Variants (http://projects.tcag.ca/variation/) currently lists 57
829 CNVs at 14 478 CNV loci and half of these CNVs are
of sizes from 1 to 10 kb. The frequency spectrum and the
precise structure of CNVs are closely related to the technical
and algorithmic methods applied (12,13). Speciﬁc CNVs
have been related to a number of complex traits–examples
are psoriasis (14), schizophrenia (15), autism (16), develop-
mental disorders (17) or HIV1/AIDS susceptibility (18). In
some instances, particular CNVs were related to certain dis-
orders as de novo events [e.g. schizophrenia (15)].
Currently,twocommonCNVregionshavebeendescribedfor
BMIandobesity.Atﬁrst,associationofacommondeletionnear
the neuronal growth regulator 1 gene (NEGR1) with BMI was
reported (8). Some CNVs are in strong linkage disequilibrium
with adjacent SNPs; therefore, this CNV was detected in a
meta-analysis of SNP data of 15 GWAS comprising more than
32 000 individuals. Recently, another common CNV (chromo-
some 10p11.22) was shown to be associated with BMI (19)i n
a Chinese sample (nominal P-value ¼ 0.011).
Inadditiontothesecommon CNVs,threerecent reports (20–
22) underlined the importance of rare, large CNVs for body
weight regulation. Two of these studies (20,21) depicted a
genomic region on chromosome 16p11.2 which harbours
highly penetrant microdeletions ( 500 kb) associated with
(extreme) obesity. This region was previously reported to be
associated with autism and mental retardation (20,21,23); in
fact, some of the obese patients analysed by Bochukova et al.
(20) additionally had developmental disorders. However, the
association of these microdeletions and obesity was also found
in individuals ascertained for obesity only (21), suggesting a
possible direct association of the deletions at 16p11.2 with
obesityapartfromthecognitivephenotype.Wangetal.(22)per-
formedagenome-wideCNVsurveyfocusingonlarge(.1 Mb)
CNVs, which were found to be over-represented in case versus
control subjects. However, to explain a substantial part of the
‘missing heritability’, thousands of such rare CNVs have to be
assumed. Recent considerations (24,25) showed that even
meta-analyses of large-scale consortia will be underpowered
to detect most of these multiple, rare variants.
The potential of common CNVs has until recently (11,26)
been largely neglected despite the fact that power issues to
detect common CNVs will be less extreme when compared
with rare CNVs. The main reason might be that samples
have often been genotyped by arrays not designed for the
detection of common CNVs. As an example, following
recent reports (13), 44% of the common CNVs detectable by
the more recent Affymetrix Genome-Wide Human SNP
Array 6.0 would not have been detected by a previous Affyme-
trix chip (Affymetrix 500K Mapping Array Set).
Here we focus on common CNVs and report a genome-wide
CNV detection and association analysis for early-onset
extreme obesity using two GWAS discovery data sets (family-
based and case–control, altogether 2160 genotyped individ-
uals) and an additional replication sample of 365 independent
obesity trios (Fig. 1).
Figure 1. Study design to discover CNVRs associated with (early-onset extreme) obesity.
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Genome-wide CNV analyses
We observed 244 autosomal common CNVRs; out of which
240 were at least partially listed in the Database of Genomic
Variants (http://projects.tcag.ca/variation). The four
yet-unknown CNVRs are positioned on chromosomes 1q25.1
(at position 173 063 167–173 068 476 bp, hg18), 3p12.1 (84
782 436–84 784 839 bp; hg18), 4q27 (122 501 906–122 504
445 bp; hg18) and 14q11.1 (18 072 112–18 183 975 bp;
hg18). With an average and median size of 183.92 and
13.97 kb, respectively, these 244 common CNVRs cover
1.56% (44.88 Mb) of the human genome (Table 1).
Among the 244 common CNVRs, we detected 25 regions
that showed suggestive evidence for an association to
(extreme) obesity in the family-based GWAS discovery
sample (two-sided asymptotic P-value in the family-based
association test for CNVs [CNV-FBAT] ≤ 0.05; Table 2 and
Fig. 2). To assess the overall impact of the 25 CNVRs on
obesity, we contrasted the effects of their correspondingly
involved CNV markers to those of randomly sampled sets of
CNV markers chosen from all CNV markers covering the ana-
lysed 244 common CNVRs. In a QQ plot (Supplementary
Material, Fig. S1), we compared the distribution of the observed
association P-values for the 1314 CNV markers covering the 25
detected CNVRs to the distribution of 1000 random sets of
P-values for 1314 CNV markers each (expectation under the
null hypothesis). We observed stronger obesity association
signals for the 25 detected CNVRs when compared with the
random distribution (Supplementary Material, Fig. S1).
These 25 CNVRs were followed up by investigating an inde-
pendent case–control GWAS sample: 20 of the 25 CNVRs also
indicated evidence for a directionally consistent association
with obesity (one-sided P ≤ 0.025; 5 of the 20 CNVRs with a
Bonferroni-corrected CNVR-adjusted one-sided P ≤ 0.025;
Table 2). Performing 10 000 permutations of the case–control
status, we observed only two permutation samples with 20 or
more of such directionally consistent associations with obesity
(empirical P-value 2 × 10
204). For 3 of the 20 CNVRs
[CNVR 10q11.22 (1), CNVR 16p13.11 and CNVR 17q21.31],
association signals for obesity were found at exactly the same
CNV marker in both GWAS discovery samples. In the remain-
ing 17 CNVRs, at least one CNV marker showed evidence for
an association with obesity in the family-based GWAS
sample, while at least one other correlated CNV marker in the
case–control GWAS sample similarly showed evidence for
an obesity association signal. The maximal pairwise correlation
coefﬁcient between each of these two CNV markers associated
with obesity ranged from 0.24 to 0.91 as estimated in the
parents, whereas the range of pairwise correlations between
those two markers with minimal P-values in the family-based
and in the case–control GWAS discovery sample was 0.15–
0.84. Among the 20 CNVRs associated with obesity, reduced
copy numbers (deletions) were associated with obesity in 18
CNVRs (Table 2).
For replication analysis of the signals in the 20 CNVRs with
evidence for an association in both GWAS samples, we
focused on a CNVR-tagging SNP approach (see Materials
and Methods section). For two (CNVR 11q11 and CNVR
1p31.1) of these regions, a tagging SNP could be identiﬁed,
which has been analysed in a third independent sample of
365 obesity trios. In addition, we also screened the 20
CNVRs in a subsample of the 365 obesity trios (281 obesity
trios) using additional Affymetrix Genome-Wide Human
SNP Array 6.0 data (array-based replication).
Table 1. Basic properties of all 244 inferred common CNVRs in our two discovery GWAS (family-based and case–control) samples
Chromosome Total
number of
CNVRs
Minimal size
of CNVRs
(kb)
Median size
of CNVRs
(kb)
Mean size of
CNVRs (kb)
Maximal size
of CNVRs
(kb)
Minimal
number of CNV
markers per
CNVR
Median number
of CNV
markers per
CNVR
Mean number
of CNV
markers per
CNVR
Maximal
number of CNV
markers per
CNVR
1 23 1.451 17.515 97.760 775.519 3 29 39.7 187
2 17 2.154 10.183 47.467 386.727 7 23 34.6 158
3 16 2.230 11.595 37.124 212.426 3 37 34.6 76
4 23 1.619 7.540 54.584 504.752 3 20 24.4 91
5 11 2.520 7.656 151.529 1440.276 6 18 18.9 52
6 12 4.137 18.423 33.696 123.822 3 22 33.2 106
7 18 0.183 12.632 34.166 170.721 3 21 21.8 44
8 18 0.202 8.552 105.523 829.942 3 23 37.8 188
9 10 2.333 77.910 2514.878 20528.869 3 12 35.6 156
10 13 0.228 10.488 106.870 570.609 3 27 33.7 161
11 5 9.682 21.760 31.977 79.570 15 46 40.6 58
12 13 1.739 5.994 25.991 115.563 4 22 22.1 41
13 6 0.254 9.287 10.321 20.136 4 17.5 18.7 37
14 8 19.882 52.329 173.045 1007.047 9 18.5 37.5 147
15 11 4.290 43.871 220.162 1768.491 3 21 59.7 371
16 8 12.351 35.853 298.688 1778.141 5 24.5 70.9 283
17 6 9.933 83.082 148.805 585.266 5 26 38.7 129
18 5 1.224 3.084 3.416 6.489 4 19 17.0 25
19 9 0.570 12.381 42.795 165.484 4 13 22.1 62
20 2 3.049 19.867 19.867 36.685 26 44 44.0 62
21 4 3.389 25.750 82.108 273.541 4 9 24.5 76
22 6 1.675 43.806 71.533 204.480 3 22 21.5 37
1-22 244 0.183 13.969 183.919 20528.869 3 22 33.0 371
842 Human Molecular Genetics, 2011, Vol. 20, No. 4Table 2. Characteristics
a of the 25 CNVRs related to obesity which were derived from the family-based GWAS discovery sample and sorted by minimal P-value
CNVR
no.
Chromosome
b Start CNVR
(bp)
b
Stop CNVR
(bp)
b
Size
CNVR
(bp)
b
Family-based
discovery
sample
Case-control discovery
sample
Corr. coeff.
(r) for best
associated
CNV
markers in
both
discovery
samples
d
Max. corr.
coeff. (r)o f
associated
CNV
marker pairs
in both
discovery
samples
d
Independent
family-based
array-based
replication
sample
Corr. coeff. (r)
for best
associated
CNV markers
in both
family-based
samples
d
Max. corr
coeff. (r)o f
associated
CNV marker
pairs in both
family-based
samples
d
Both
e
family-based
samples
min. P-value,
single marker
analyses
min. P-value,
single marker
analyses
CNVR-
adjusted
P-value
c
min. P-value,
single marker
analyses
CNVR
adjusted
P-value
c
1
f 11q11 55130596 55210 165 79569 0.0047 1.58 3 10
205 0.0003 0.5 0.75 0.0021 0.69 Same marker 0.0080
2 4q32.1 161282532 161 289730 7198 0.0048 6.77 3 10
204 0.0071 0.56 0.56 0.0726 – – 0.0210
3 16p13.11 14796084 14987 969 191885 0.0076 3.08 3 10
204 0.0149 0.47 Same
marker
0.1635 – – 0.2470
4
f 1p31.1 72541074 72583 749 42675 0.0084 0.0068 0.0824 0.56 0.84 0.0054 0.85 Same marker 0.0090
5 3q21.3 131245537 131 290979 45442 0.0096 4.52 3 10
205 0.0015 0.68 0.86 0.0854 – – 0.1330
6 4q25 108285188 108 293270 8082 0.0098 2.21 3 10
204 0.0043 0.32 0.40 0.0707 – – 0.1180
7 2q32.1 184502747 184 510699 7952 0.0117 0.0091 0.0866 0.71 0.71 0.2769 – – 0.0920
8 6p21.32 32560895 32638 289 77394 0.0122 0.0140 0.1794 0.24 0.24 0.0339 – – 0.1260
9 3q22.1 133475451 133 478387 2936 0.0126 0.5089 0.7367 ––– – – –
10 5q13.2 68903038 70343 313 1440275 0.0126 1.10 3 10
205 <0.0001 0.69 0.73 0.2250 – – 0.1240
11 15q13.2 28280641 28609 063 328422 0.0130 5.60 3 10
207 <0.0001 0.52 0.70 0.0174 0.55 0.59 0.1690
12 10q21.1 58186369 58196 856 10487 0.0167 5.39 3 10
204 0.0161 0.69 0.89 0.3043 – – 0.2370
13 10q11.22 (1) 46338178 46812 351 474173 0.0188 1.00 3 10
206 0.0004 0.84 Same
marker
0.0169 0.89 0.89 0.1460
14 3p11.1 89477270 89499 280 22010 0.0192 0.0072 0.1811 0.67 0.68 0.1139 – – 0.2160
15 2p22.1 41091935 41099 404 7469 0.0195 1.79 3 10
204 0.0022 0.68 0.87 0.0611 – – 0.1340
16 19p12 20388034 20508 242 120208 0.0195 3.77 3 10
204 0.0133 0.6 0.91 0.0775 – – 0.1420
17 3q29 194360584 194 365610 5026 0.0197 0.3528 0.9132 ––– – – –
18 4p16.1 9832714 9844 379 11665 0.0225 0.3266 0.9075 ––– – – –
19 1p36.1 25468522 25534 812 66290 0.0226 0.0935 0.5809 ––– – – –
20 10q11.22 (2) 47011183 47145 122 133939 0.0229 2.93 3 10
205 0.0016 0.3 0.54 0.0147 0.59 0.59 0.1140
21 17q21.31 41522227 42107 492 585265 0.0231 1.17 3 10
204 0.0061 0.75 Same
marker
0.0038 0.20 0.65 0.4130
22 12p13.31 9525125 9604 954 79829 0.0233 0.0577 0.2734 ––– – – –
23 8p23.2 5586122 5591 428 5306 0.0237 0.0114 0.1465 0.73 0.73 0.1491 – – 0.1620
24 1q21.1 147182865 147 958383 775518 0.0243 2.70 3 10
206 0.0002 0.15 0.28 0.0309 – – 0.3270
25 6q14.1 81340896 81346 266 537 0.0246 1.76 3 10
204 0.0035 0.59 0.69 0.2045 – – 0.1080
aGrey rows (1-2,4-17,20-24) indicate regions with evidence for an association with deletions being associated with obesity (as based on the family-based GWAS discovery sample). The 20 directionally
consistent results based on both GWAS discovery samples are highlighted in bold (requiring a minimum CNV marker-wise one-sided P-values ≤ 0.025 in the case–control GWAS discovery sample).
bChromosomal positions are based on genome build hg 18.
cFor details on CNVR-adjusted P-values (based on 10 000 permutations) see section on Permutations and Multiple Testing). Those adjusted P-values that remain signiﬁcant after Bonferroni correction for the
25 CNVRs tested are underlined.
dFor details on the CNV marker correlation, see Quality control section.
e‘Both family-based samples’ refers to the family-based discovery GWAS data set and the independent array-based replication data set of families.
fFor those two CNVRs the following CNVR-tagging SNPs could be identiﬁed: CNVR 11q11 – rs9804659, CNVR 1q31.1 – rs2815752.
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3Replication and exploration of CNVR 11q11
The CNVR on chromosome 11q11 (CNVR 11q11) was the best
CNVR(accordingtoP-valueinthefamily-basedGWASsample;
min. Pfamily-based ¼ 0.0047) among the set of 20 CNVRs which
were directionally consistently associated with obesity in both
GWAS discovery samples (with correlation coefﬁcients up to
r ¼ 0.75 for pairs of associated CNV markers in the two
samples; Table 2). CNVR 11q11 was similarly supported in the
multi-marker analysis (min. P ¼ 8.66 × 10
24; Fig. 3). This
CNVRrepresentsalocuspreviouslynotreportedtobeassociated
withobesity.Itislocatedbetween55130596and55210165 bp
spanning  80 kb. Interestingly, the region exclusively covers
three olfactory receptor (OLR) genes: OR4P4, OR4S2 and
OR4C6 (according to RefSeq of UCSC hg18; http://genome.
ucsc.edu/) all belonging to the OLR family 4.
We followed CNVR 11q11 up in the replication sample of
365 independent obesity trios due to the availability of a
CNV-tagging SNP (rs9804659) and observed a directionally
consistent trend for an association to obesity with a one-sided
P-value of 0.076 [odds ratio for the obesity effect allele
(OR) ¼ 1.188; 95% conﬁdence interval (CI) ¼ 0.939–1.502].
The maximal squared Pearson correlation (r
2) between
rs9804659 and any of the CNV markers in CNVR 11q11
was 0.65, while r
2 was 0.53 between rs9804659 and the best
associated CNV marker (minimal P-value in the family-based
discovery sample; Table 3). Thus CNVR 11q11 is not that well
tagged by rs9804659, which might explain why the P-value in
the replication is an order of magnitude lower than in the dis-
covery sample.
Consequently, given this moderate correlation, for technical
validation and further analyses, we re-assessed CNVR 11q11
by quantitative real-time polymerase chain reaction (qPCR)
in the family-based GWAS discovery sample and in the
family-based replication sample of 365 case-parents obesity
trios. On the basis of the qPCR ﬁndings, we validated
CNVR 11q11 as a biallelic deletion region with a minor
allele frequency of 28% in the set of all 789 parental pairs.
We observed 7.71% homozygotes and 40.35% heterozygotes
for the deletion in the parents. In obese offspring, we detected
9.72% homozygotes and 40.03% heterozygotes. Thus, the
number of homozygous deletions was slightly increased in
the obese offspring, which was consistent with the observed
transmission disequilibrium. The analysis of the qPCR-
validated copy number calls in the family-based GWAS dis-
covery sample indicated a trend towards preferable trans-
mission of the 11q11 deletion to obese children (OR ¼
1.171; 95% CI ¼ 0.947–1.448; one-sided P ¼ 0.066). A
similar qPCR-based analysis in the replication sample revealed
a directionally consistent ﬁnding (OR ¼ 1.214; 95% CI ¼
0.959–1.537; one-sided P ¼ 0.056). Finally, we performed a
joint analysis of all case-parents trios (discovery and replica-
tion sample) to increase the precision of the estimator, result-
ing in an OR of 1.190 for the deletion allele (95% CI ¼
1.016–1.394; one-sided P ¼ 0.015).
Array-based replication analysis
All 20 CNVRs with evidence for an association with obesity in
both GWAS discovery samples were followed up in 281 inde-
pendent obesity trios (a subsample of the 365 independent
obesity trios analysed at the two tagging SNPs) that were
very recently genotyped (Affymetrix Genome-Wide Human
SNP Array 6.0). Six of the 20 CNVRs again showed evidence
for a directionally consistent association with obesity (one-
sided CNV-FBAT P-value ≤ 0.025; Table 2). These six
CNVRs involve those two CNVRs that are also supported by
the tagging SNP approach. Furthermore, association signals
for only these two CNVRs were found at exactly the same
CNV markers as in the family-based discovery GWAS
Figure 2. Genome-wide distribution of the 244 common CNVRs estimated in
our discovery GWAS (family-based and case–control) samples. CNVRs are
graphically represented by black bars according to their chromosomal position
and size (genome build hg 18).
Figure 3. Results for CNVR 11q11 in the family-based (ﬁlled circles) and in
the case–control (open circles) GWAS discovery sample. Additionally, multi-
marker FBAT results are plotted as grey lines representing the P-values
achieved in the test incorporating each CNV marker covered by the line.
844 Human Molecular Genetics, 2011, Vol. 20, No. 4sample. Neither in the family-based discovery nor in the array-
based replication sample did any of the CNVRs achieve sig-
niﬁcant CNVR-adjusted P-values (all .0.025; data not
shown). However, in a combined analysis of both family-based
samples, three CNVRs presented at least nominally signiﬁcant
CNVR-adjusted one-sided P-values (≤0.025; Table 2). None
of these CNVR associations remained signiﬁcant after strict
Bonferroni correction, which may potentially be due to an
insufﬁcient sample size. Among the three CNVRs with nomin-
ally signiﬁcant CNVR-adjusted P-values, again those two
CNVRs tagged by SNPs were found. Additional support was
given for CNVR 4q32.1, which does not comprise any gene.
Previously reported CNVs in our genome-wide
CNV analysis
CNVR 1p31.1 (Table 2) 20 kb upstream of NEGR1 was the
only CNV associated with BMI in a meta-analysis of 15
GWAS (8). Identiﬁcation of the CNV was based on SNP
tagging in a large meta-analysis of population-based samples
of European origin. We were able to conﬁrm this CNVR in
both of our GWAS discovery samples (min. Pfamily-based ¼
0.0084; min. Pcc ¼ 0.0068 for different CNV markers) while
we observed stronger signals in the family-based GWAS
sample (Fig. 4). Moreover, CNVR 1p31.1 is one of the two
CNVRs (out of 20) that could be tagged by an SNP
(rs2815752). The major allele T of rs2815752 is tagging the
deletion allele of CNVR 1p31.1. Analysis of the
CNVR-tagging SNP in the replication sample (365 indepen-
dent obesity trios) again underlined the obesity association
(OR ¼ 1.277; 95% CI ¼ 1.021–1.597; one-sided P-value ¼
0.0157; Table 3). In a joint analysis of the two family-based
samples at rs2815752, we estimated an OR of 1.214 (95%
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Figure 4. Results for CNVR 1p31.1 (20 kb upstream of NEGR1) in the family-
based (ﬁlled circles) and in the case–control (open circles) GWAS discovery
sample. Additionally, multi-marker FBAT results are plotted as grey lines
representing the P-values achieved in the test incorporating each CNV
marker covered by a line.
Human Molecular Genetics, 2011, Vol. 20, No. 4 845CI ¼ 1.046–1.408, one-sided P-value ¼ 0.0052). Additional
support for this CNVR was provided by the array-based repli-
cation analysis (see above).
In addition to CNVR 1p31.1, the other previously reported
common CNVR associated with BMI (nominal P-value
0.011) was located on chromosome 10q11.22 which was
initially described in an adult Chinese population-based
sample (19). In our study, this CNVR [CNVR 10q11.22 (1)]
was also among those 20 candidates with evidence for associ-
ation with obesity in both GWAS discovery samples. In
addition, this CNVR is among those three candidates with evi-
dence for association at exactly the same CNV marker (located
between 46 478 786 to 46 478 811 bp with a combined
P-value ¼ 1.13 × 10
26 in the two GWAS samples). In the
case–control GWAS sample, the number of associated CNV
markers was relatively large (47 of 161 CNV markers with
P ≤ 0.025; Fig. 5). Moreover, CNVR 10q11.22 (1) is among
those 6 CNVRs with a minimal one-sided CNV-FBAT
P-value ≤ 0.025 in the array-based replication analyses.
CNVR 10q11.22 (1) (Table 2) covers four genes: (i) the pan-
creatic polypeptide receptor 1 (PPYR1) was a member of the
seven transmembrane domain-G-protein-coupled receptor
family and pancreatic polypeptide (PP) is a potent anti-obesity
agent known to inhibit food intake (27), (ii) Synaptotagmin
XV (SYT15), (iii) the G protein regulated inducer of neurite
outgrowth 2 (GPRIN2) and (iv) the heterogeneous nuclear
ribonucleoprotein A1 pseudogene (LOC728643).
Beyond the focus of this study on common CNVRs for
early-onset (extreme) obesity, we also explored selected
regions harbouring rare CNVs (20,21). First, we looked at del-
etions on chromosome 16p11.2 (28.4–31.0 Mb) of at least
593 kb in both of our GWAS samples (21). In the family-based
GWAS sample, we exclusively found one obese patient with a
heterozygous de novo deletion of 709 kb. Moreover, in the
case–control GWAS sample, four obese cases but none of
the controls were called for heterozygous deletions with
sizes between 709 and 894 kb (one-sided P-value of Fisher’s
exact test ¼ 0.13). Secondly, we compared the list of rare
recurrent CNVs found in patients with severe early-onset
obesity (20) to the common CNVRs determined here. We
observed no exact overlap, which was not unexpected given
our focus on common CNVs. However, 2 of the 12 CNVs
reported for patients with severe early-onset extreme obesity
(20) were 133 kb downstream and 66 kb upstream of the
CNVRs detected here (CNVR 3p11.1 and CNVR 15q13.2;
Table 2). Both these CNVRs showed evidence for association
with obesity in both of our GWAS discovery samples (3p11.1:
min. Pfamily-based ¼ 0.019; min. Pcc ¼ 0.0072 for different
CNV markers with maximum correlation r ¼ 0.68; 15q13.2:
min. Pfamily-based ¼ 0.013; min. Pcc ¼ 5.5 × 10
27 for different
CNV markers with maximum correlation r ¼ 0.70).
DISCUSSION
We performed a genome-wide analysis of common copy
number variations (CNVs) in two discovery samples ascer-
tained for early-onset (extreme) obesity. We observed 244
CNVRs that covered  1.56% of the genome-most of these
regions were already known from databases. Among the 244
CNVRs, we detected 20 regions that were directionally con-
sistently associated with obesity in both discovery samples.
Among these 20 associated regions, we identiﬁed a new
CNVR 11q11 associated with early-onset (extreme) obesity.
While the presence of copy number variability at CNVR
11q11 is well established (28–30), its relationship to obesity
has not been described before. CNVR 11q11 covers the
three protein coding genes OR4P4, OR4S2, OR4C6 (according
to RefSeq of UCSC hg18; http://genome.ucsc.edu/) of the
OLR family 4. OLRs interact with odorant molecules in the
nose, to initiate a neuronal response that triggers the percep-
tion of a smell. They form the largest mammalian protein
superfamily. There is a high percentage ( 55%) of human
pseudogenes (29). The OLR proteins are members of the
family of G-protein-coupled receptors arising from single-
coding exon genes.
It was hypothesized that CNVs play an important role in the
evolution of the human olfactory repertoire (29). About half of
the CNVs affecting the human OLR repertoire involve more
than one OLR. It was also observed that CNVs were more fre-
quent among pseudogenes of OLRs than among functional
genes (29). Comparison to the chimpanzee, reference
genome revealed that all of the detected deletion alleles are
human derived. This indicated a profound effect of human-
speciﬁc deletions on the individual OLR gene content. It
was suggested that these deletion alleles may be used in
future genetic association studies of olfactory inter-individual
differences (29). Evidence was provided for OLR enrichment
in CNVs not being due to positive selection but due to the
dominance of OLR in segmentally duplicated regions (30).
Additionally, purifying selection against CNVs is lower in
regions containing OLRs than in regions containing essential
genes (30). A possible link between OLRs and obesity has
Figure 5. Results for CNVR 10q11.22 (1) in the family-based (ﬁlled circles)
and in the case–control (open circles) GWAS discovery sample. Additionally,
multi-marker FBAT results are plotted as grey lines representing the P-values
achieved in the test incorporating each CNV marker covered by a line.
846 Human Molecular Genetics, 2011, Vol. 20, No. 4previously been suggested based on the observation of altered
olfactory acuity in morbidly obese patients (31).
Additionally, within the 20 associated regions, we con-
ﬁrmed two previously published obesity associations: CNVR
1p31.1 20 kb upstream of NEGR1 (7,8) and CNVR 10q11.22
(1) covering the four genes SYT15, GPRIN2, LOC728643
and PPYR1 (19) with PPYR1 being the most interesting candi-
date, given its role in energy homeostasis and regulation of
food intake (27,32). PPYR1 null animals have, for instance,
a reduced body weight. PP reduces food intake predominantly
via stimulation of the anorexigenic melanocortinergic
pathway. This effect is mediated by direct action on local
PPYR1 within the arcuate nucleus (32). PP binds to the
PPYR1. In our study as well as in the previous study which
initially described the association of CNVR 10p11.22 (1)
with BMI (19), the loss of a PPYR1 gene copy number was
associated with obesity. Among those individuals (n ¼ 57) of
our two GWAS discovery samples that were called for the
loss of a PPYR1 gene copy number, only one was homozygous
for the deletion. One can only speculate about these seemingly
contradictory ﬁndings between studies in human and mice.
Several mechanisms might explain the difference: (i) mice
may not be the most appropriate model to understand the func-
tion of the human PPYR1, as mice express a functional Y6
receptor (in humans only an non-functional pseudo gene
exists) and this receptor could explain some of the results of
the Ppyr1 knockout mice. (ii) Sequence identity between
mice Ppyr1 amino acid sequence is only 76% compared with
human PPYR1. The high variability of PPYR1 across
species might explain its different roles among species. (iii)
Ppyr1 knockout mice are hyperphagic but nonetheless lean
(27). If the gene has a slightly altered function in humans,
hyperphagia is potentially retained but not the lean phenotype.
(iv) Compared with the 56 studied subjects who are hemizy-
gous for the PPYR1 gene, Ppyr1 knockout mice have neither
copy of the gene nor corresponding gene expression products.
Thus, subjects with only one copy of PPYR1 may produce less
protein, which will regulate energy homeostasis through ago-
nists or other pathways to inhibit obesity. In contrast, knockout
mice have neither copy of the gene nor the corresponding gene
expression products, which may also explain the difference
between human studies and mice experiments.
While the replications of previous ﬁndings underline the
strength of our study, the focus on consistently associated
common CNVs for early-onset (extreme) obesity using an
agnostic genome-wide approach is also accompanied by weak-
nesses. First of all, our follow-up/replication step using
tagging SNPs has focused on only 2 of all 20 candidate
CNVRs-albeit those with the strongest association signals.
Thus, it is conceivable that additional regions could be true
positive ﬁndings. However, given their weaker association
signals in both of our deletion samples, larger replication
samples than the one used by us will be required to rule out
false-negative ﬁndings. This is underlined by the results of
our array-based replication analyses supporting four additional
CNVRs of all 20 candidate CNVRs. Secondly, our study
clearly has limited detection power to comprehensively
assess CNV at a genome-wide level. None of the tested
CNVs achieved a stringent genome-wide signiﬁcance level
and for those that could be replicated only moderate effects
(odds ratio of  1.2) were observable. Thus, our observation
for early-onset (extreme) obesity underlines the recent
ﬁnding that common CNVs are unlikely candidates to
explain larger parts of the ‘missing heritability’ (26). Finally,
it has to be underlined that the focus on CNVRs is
accompanied by (a) the difﬁculty to deﬁne the CNV markers
that make up a CNV and (b) the difﬁculty to assess when
and if association signals in different samples pertain to the
same source. Here both problems have been dealt with by pro-
viding upper limits of correlations among associated CNVs of
independent samples and by omitting combined P-values
across samples.
Since we replicated two CNVRs using tagging SNPs, their
association could have already been detected by genome-wide
SNP association studies. Indeed, rs2815752 (tagging CNVR
1p31.1) near NEGR1 is a well-known and well-replicated
BMI locus (8,33). In contrast, for rs9804659 (tagging CNVR
11q11), no association to obesity, BMI or waist–hip ratio
has yet been reported in the primarily population-based
genetic association studies of adults (33,34).
Very recently, another 21-kb CNV that lies 50 kb upstream
of the gene GPRC5B has been reported to be associated with
BMI (33). The identiﬁcation of this CNV was based on the
tagging SNP rs12444979 in a large meta-analysis for
population-based samples, whereas the deletion allele of the
CNV is tagged by the non-risk allele of the SNP. We could
also identify this CNV as one of the 244 common CNVRs ana-
lysed here. However, a signiﬁcant association with early-onset
(extreme) obesity was observed only in our case–control
GWAS discovery sample (one-sided min. PCC ¼ 0.0066 and
min. Pfamily-based ¼ 0.0408 for the non-deletion direction).
Owing to our focus on common CNVs, the role of rare del-
etions or duplications has only been addressed here, by explor-
ing selected loci harbouring known rare CNVs in extreme
obese patients (20,21). In order to comprehensively investigate
whether certain rare CNVs [e.g. large (.1 Mb) CNVs (cf. 22)]
predispose to obesity, a more comprehensive quality control
(QC) and validation of each single CNV call as well as a
much larger adequately powered analysis sample is needed.
It is conceivable that such assessments will become feasible
within large-scale consortia such as GIANT [Genetic Investi-
gation of ANthropometric Traits (8)].
In summary, we provide evidence for a new common
CNVR for early-onset (extreme) obesity on chromosome
11q11 covering the coding regions of OLR genes. Moreover,
we conﬁrmed two previously described common CNVRs for
obesity. Overall, however, common CNVRs seem to be of
minor importance to account for the ‘missing heritability’ of
early-onset (extreme) obesity.
MATERIALS AND METHODS
Study subjects
Detection of common CNVRs and initial association analyses
were based on two GWAS discovery samples both genotyped
by the Affymetrix Genome-Wide Human SNP Array 6.0. The
family-based GWAS sample (Sample 1) consists of 424
obesity trios, i.e. one (extremely) obese child or adolescent
and both biological parents (Supplementary Material,
Human Molecular Genetics, 2011, Vol. 20, No. 4 847Table S1). The second GWAS sample (Sample 2) consists of
453 (extremely) obese children and adolescents and 435
normal-weight or lean adult controls (Supplementary Material,
Table S1). For replication of the association of certain CNVs
with obesity as derived from both GWAS samples, we ana-
lysed a third independent sample of 365 obesity trios
(Sample 3) which was recruited similarly as the family-based
GWAS sample (Supplementary Material, Table S1).
Additional array-based replication analyses were performed
in a subsample of Sample 3 consisting of 281 obesity trios
for which genome-wide genotyping data (Affymetrix Genome-
Wide Human SNP Array 6.0) became available very recently
(Sample 3a).
In all three samples, the measured BMI (in kg/m
2) was
assessed for extremeness using age- and sex-speciﬁc percentile
criteria for the German population (35). According to this
reference population, all cases (cases of the case–control
sample and offspring of the two family-based samples) were
at least overweight (percentile ≥ 90th). Most of the cases
were extremely obese (percentile ≥ 97th): 93.6% of the
index cases of the family-based GWAS sample, 92.5% of
the cases in the case–control GWAS sample as well as
91.5% of the offspring from the family-based replication
sample.
Written informed consent was given by all participants and,
in case of minors, by their parents. The study was approved by
the Ethics Committees of the Universities of Marburg and
Essen and conducted in accordance with the Declaration of
Helsinki.
CNVs calling and CNVRs determination
CNVs calling. In both GWAS discovery samples, genotyping
was carried out using the Affymetrix Genome-Wide Human
SNP Array 6.0. Besides 906 703 SNP probes (869 747 autoso-
mal), this chip contains 943 390 non-polymorphic additional
probes (888 023 autosomal) for copy number analyses (http://
www.affymetrix.com). The autosomal ﬂuorescent intensities
at the non-polymorphic probes were used as a measure of
copy number variance for the primary statistical analysis. This
was done to avoid the loss of information and power related to
CNV calling (36,37). The intensity values were extracted from
the individual CEL ﬁles utilizing the R-package ‘affxparser’.
We normalized the raw intensities of the case–control GWAS
sample by performing quantile normalization (38) to address
potential chip effects. In case of the family-based GWAS
sample, we analysed the raw ﬂuorescent intensities since the
family-based design allows for controlling the inter-individual
variability.
As secondary sensitivity analysis in both GWAS discovery
samples, we investigated the called CNV states at a genome-
wide level, i.e. the unphased total number of copies at a
genomic locus. We determined CNV calls for each individual
and each marker using the Affymetrix Genotyping Console
3.0. In particular, we applied a ﬁve-state hidden Markov
model (HMM) (39) to smooth and segment the data with
default values of 0.2 for each prior probability and 1000 Mb
as a transition decay. The ﬁve possible HMM copy number
states (CNS) were: 0, homozygous deletions; 1, heterozygous
deletions; 2, (normal) diploid case; 3, single copy gains; 4+,
cases of four or more copies. The CNV calling requires com-
parison of individual signal intensities against a reference
sample. Owing to computational constraints, we processed a
reference sample of 106 parental pairs from the family-based
GWAS sample. To check whether and to what extent the
choice of the reference sample had an impact on CNS
calling, we decided to choose two different reference
samples, each comprising 106 parental pairs. Reference
Sample 1 was a random sample of all parental pairs,
whereas reference Sample 2 was based on those 106 parental
pairs with the lowest mean BMI standard deviation score
values out of all non-obese parental pairs (percentiles ,
90th) in our sample (see Supplementary Material, Table S1
for details). In both GWAS discovery samples, we performed
CNV calling based on either of the two reference samples and
proceeded only those variations that were consistently
assigned via both approaches (see QC and association testing
section).
CNVRs determination. A CNV has been deﬁned as a DNA
segment that is 1 kb or larger and is present at variable copy
numbers in comparison with a reference genome (40). Copy
number variable regions (CNVRs) are regions covered by
overlapping CNVs (41). The copy number characterization
of 270 HapMap samples showed that  80% of observed
copy number differences between pairs of individuals were
due to common CNVs with an allele frequency of .5%,
and .99% were derived from inheritance rather than from
new duplication/deletion events (13). According to published
recommendations (13,41), we deﬁned common CNVRs as
regions covering at least three consecutive CNV markers
showing deletions or duplications in at least 5% of each set
of GWAS cases, parents and controls. Thus, if several individ-
ual CNVs overlapped, we merged them in the same CNVR, so
that most CNVRs represent a union of overlapping CNVs
(19,42). For details on the resulting 244 CNVRs based on
8051 CNV markers with genomic positions based on
genome build hg 18 (March 2006), see Table 1 and Figure 2.
CNV validation and replication
Validation of CNVR 11q11 by qPCR. The most promising new
region detected in the two GWAS samples, a CNVR at
chromosome 11q11 (CNVR 11q11), was technically validated
in the family-based GWAS sample using qPCR to ensure
reliability of the chip-based CNVR detection and for
additional analyses based on precise individual copy number
calls. In more detail, we applied real-time quantitative PCR,
using a Duplex TaqMan CNV assay (Applied Biosystems,
Germany; assay Hs03802074_cn at chr11:55 203 791+
50 bp) as described previously (43). Brieﬂy, every reaction
was performed as a triplicate and the results for the qPCR
were analysed using the software CopyCaller 1.0 (Applied
Biosystems). Overall, the correlation between continuous
intensity-based CNV calls used for association testing and
continuous qPCR predicted calls was estimated to be 0.87
(Pearson correlation coefﬁcient). Using qPCR approximately
half of the individuals of the family-based sample were ident-
iﬁed as carriers of a heterozygous or homozygous deletion at
CNVR 11q11. Regarding called CNS the data were not
848 Human Molecular Genetics, 2011, Vol. 20, No. 4readily comparable. Hence, all called 105 homozygous del-
etions at CNVR 11q11 were called by both qPCR and Affyme-
trix CNV markers whereas the overlap for called heterozygous
deletions (n ¼ 510 called by qPCR) was exceedingly lower
(only 3% of all 510 heterozygous deletions were calculated
as CNS ¼ 1 by the HMM applied to the Affymetrix CNV
markers). Taken together, the latter observation corresponds
to the results of others (44) and underlines the beneﬁts of
using intensities as compared to the use of called CNVs.
For further analysis of the CNVR 11q11 signal, in the inde-
pendent sample of 365 obesity trios copy number status was
also assessed by the qPCR assay described above, resulting
in similar proportions for heterozygous and homozygous del-
etion carriers.
CNVR-tagging by SNPs. CNVRs and the surrounding+
500 kb DNA segments with evidence for an association to
obesity as based on the CNV-FBAT (family-based GWAS
sample; at least one marker with a two-sided asymptotic
P-value ≤ 0.05) and with additional evidence for association
as based on the logistic regression (case-control GWAS
sample; at least one marker with a directionally consistent two-
sided asymptotic P-value ≤ 0.05), were analysed with the aim
to identify SNPs that are in linkage disequilibrium with the
involved CNVs (see 26). It was reported that CNVs that
were well genotyped were frequently tagged by SNPs (26).
Again circumventing the calling, we determined Pearson cor-
relations of intensity values for CNVs and SNPs in the set of
all 424 parental pairs of the GWAS trios. For a CNVR-tagging
SNP we required that the squared Pearson correlation coefﬁ-
cient (r
2) of intensities had to be .0.6 for at least three con-
secutive CNV markers. CNVR-tagging SNPs were detected
for two of the 20 CNVRs assessed. These two SNPs
(rs9804659, rs2815752) were followed-up for replication
association analyses in the sample of 365 independent case-
parents obesity trios.
QC and association testing
Quality control. All individuals of both GWAS samples under-
went SNP marker QC as described previously (4,45). In detail,
QC ﬁlters for individuals were checked for Mendelian incon-
sistencies in the family-based GWAS sample (.5% of all
SNPs), the application of an SNP call rate of 95% and a
minimum genotyping quality as assessed by Affymetrix Con-
trast QC . 0.4.
Regarding QC of the CNVR determination, we limited
our analyses to CNVRs for which the genomic variability-
irrespective of phenotype (i.e. in cases, controls, parents and
offspring)-was at least 5% based on each of the two reference
samples used for copy number calling (Supplementary
Material, Table S1). The mean individual concordance rates
between the use of both reference samples for called CNSs
0, 1, 3 and 4+ were 97.83% (range: 84.67–99.90%) in the
family-based GWAS sample and 94.53% (range: 83.61–
99.79%) in the case–control GWAS sample.
Concerning the genome-wide agreement between CNVR
calling in both discovery GWAS samples, a total of 880
CNVRs with frequencies .1% which cover ≈15% of the
genome have been called in the family-based discovery
GWAS sample. Of these CNVRs, 97.04% were again called
as CNVRs in the case–control discovery GWAS sample.
Even among those CNVRs that were found in at least two indi-
viduals (6473) in the family-based discovery GWAS sample,
83.5% were redetected as CNVRs in the case–control discov-
ery GWAS sample. CNVRs called in just one individual are
more likely false positives compared with CNVRs identiﬁed
in several individuals and are thus neglected here.
When focusing on CNVRs, comparability of association
ﬁndings across samples needs to be addressed as different indi-
vidual CNV markers might contribute to the association in
different samples. We determined pairwise Pearson corre-
lations between pairs of selected CNV marker intensity
values in each of the two discovery GWAS samples. The
selection was based on the presence of some evidence for an
association with obesity for the CNVR (family-based
GWAS: two-sided asymptotic P-value in CNV-FBAT ≤
0.05; case–control GWAS: directionally consistent two-sided
asymptotic P-value in logistic regression ≤ 0.05). We report
the maximal Pearson correlation coefﬁcient (r) computed
from the set of selected CNV markers (Table 2, 10th
column). For comparability, we also report the Pearson corre-
lation coefﬁcient (r) for those two CNV markers with minimal
P-values in the family-based and in the case–control discov-
ery GWAS samples, respectively (Table 2, 9th column).
Concerning the QC related to the qPCR experiments for
CNVR 11q11, only those copy number calls with a conﬁdence
value (by CopyCaller 1.0) of at least 0.98 without evidence for
Mendelian inconsistencies were followed-up. Subsequently,
the full set of all 772 families successfully assessed by
qPCR was analysed for deviations from Hardy–Weinberg
equilibrium (46) resulting in a two-sided exact P-value of
0.95 in the parents.
For QC of the CNVR-tagging SNP genotypes (at rs9804659
and rs2815752) in the replication sample of 365 case-parents
obesity trios, an exact test for deviations from Hardy–Wein-
berg equilibrium (46) was performed in the set of parents
(minimal two-sided exact P-value across both SNPs ¼ 0.33).
Association testing. In each sample, we analysed the associ-
ation between CNVs and (extreme) obesity. All primary ana-
lyses of the GWAS discovery samples were based on
ﬂuorescent intensities which represent the copy numbers. For
the family-based GWAS sample, we applied the CNV-FBAT
methodology (37) to test the raw intensities for association
with the phenotype obesity. We based our association tests
on the raw intensities in order to avoid the known loss of infor-
mation and statistical power resulting from classifying raw
copy number measurements into discrete classes, i.e. CNV
calls (36,37). To reduce the number of statistical tests and to
minimize the risk of false-positive ﬁndings, the CNV-FBAT
association tests were limited to the common CNVRs
derived as described above. Additionally, we performed multi-
marker FBATs (35) incorporating all possible marker combi-
nations in a speciﬁc CNVR. The case–control GWAS
sample was analysed by logistic regression with the predictors
normalized intensities, sex and age.
Regarding the study design we focused on CNV testing in
the family-based discovery sample as a ﬁrst step while using
the case–control discovery GWAS sample as secondary
Human Molecular Genetics, 2011, Vol. 20, No. 4 849discovery ﬁlter. The focus on our family-based sample has
several advantages: (i) the known robustness of the family-
based design against population stratiﬁcation; (ii) better
control for biases (e.g. plate effects) due to the within-family
comparisons; (iii) due to the incorporation of only one affected
offspring per pedigree, the CNV-FBAT leads to quite conser-
vative results, which lowers the risk of false positives. The
conservativeness of the CNV-FBAT is displayed in the QQ
plots for the two discovery samples (Supplementary Material,
Fig. S2). In contrast to the CNV-FBAT, the results for the
case–control analyses are too liberal although we performed
normalizations of the intensity signals to, for example,
address technical problems (e.g. plate effects).
To derive CNVRs for replication using CNVR-tagging
SNPs, we ﬁrst focused on those estimated CNVRs which
showed some evidence for association to obesity in the family-
based GWAS sample (CNV-FBAT test; at least one marker
with a two-sided asymptotic P-value ≤ 0.05). Taking into
account whether this CNVR indicated gain or loss for the
obesity association, we then calculated CNV marker-speciﬁc
one-sided P-values for the tests in the case–control GWAS
sample. For clarity (if not stated otherwise), all reported
P-values are one-sided, nominal, i.e. unadjusted for multiple
testing, and asymptotic.
In the independent replication sample of obesity trios, we
genotyped the two identiﬁed CNVR-tagging SNPs. For
detailed analysis of the CNVR 11q11, this was additionally
genotyped by qPCR in the family-based replication sample.
For the CNVR-tagging SNPs, we applied the classical trans-
mission disequilibrium test (TDT) (47). Replication analysis
of the qPCR-typed CNVR 11q11 was performed by appli-
cation of the CNV-FBAT on the derived copy number calls.
Odds ratios (ORs) were calculated by applying the haplotype
relative risk method (48), which uses the transmitted parental
alleles as a case sample and the untransmitted parental alleles
as a control sample.
For additional array-based replication analyses of the 20 dis-
covered CNVRs in a sample of 281 independent obesity trios,
intensity values for each involved marker were again extracted
with the R-package ‘affxparser’. As for the family-based dis-
covery GWAS sample, the CNV-FBAT methodology was
applied to the raw intensities afterwards. Finally, one-sided
P-values were calculated by taking into account the estimated
CNVR effect direction as based on the family-based discovery
GWAS sample.
Permutation and multiple testing. Under the null hypothesis of
no marker-phenotype associations, the intensity distribution
at each marker is independent of the family status (i.e.
father, mother, child) in the family-based samples and inde-
pendent of the affection status (i.e. case, control) in the
case–control sample. Thus, in order to simulate the test stat-
istics distributions under the null hypothesis, we permuted
family status (and family labels) or affection status, respect-
ively, several times; each time storing the corresponding
test statistics. Following this procedure, marker-wise approxi-
mate exact P-values were then calculated by dividing the
number of observed permutations achieving an equal or
higher test statistic for this marker than the actually observed
one by the number of permutations performed. The QQ plots
in Supplementary Material, Figure S3 demonstrate the val-
idity of this approach and of the asymptotical P-values by
comparing the quantiles of the 8051 true (asymptotic)
observed P-values in the 244 common CNVRs with those
quantiles of approximate exact P-values based on 1000 per-
mutations in the case–control sample and the family-based
sample, respectively. Note that here, deviations from the
diagonal line for the case–control sample result from the
limited number of permutations performed. CNVR-wise
approximate exact (called CNVR-adjusted) P-values were
calculated analogously by taking into account that several
CNV markers have been tested for each CNVR. Thus here,
for each permutation and each CNVR, the maximum over
all CNV markers test statistics was compared with the
maximum of the observed test statistic. In order to achieve
one-sided exact P-values, we additionally stored and com-
pared the direction of the effect.
To address the genome-wide multiple testing problem of
our report, we also performed additional analyses. First, to
address the impact of the 25 CNVRs detected in the family-
based GWAS discovery sample, we stored the CNV-FBAT
P-values of the respective 1314 CNV markers (those with
two-sided asymptotic P-values ≤ 0.05; Table 2). Next, we
drew 1000 random sets of 1314 CNV markers out of the
244 analysed CNVRs (8051 CNV markers) to derive the dis-
tribution of P-values under the null hypothesis. Next, both
the quantiles of –log10 P-values of observed association
signals and the corresponding 97.5, 50 and 2.5% percentiles
of the 1000 random sets of equal size were plotted against
the expected quantiles (from a uniform distribution) in a
QQ plot (Supplementary Material, Fig. S1). While both the
observed and sampled results indicated the conservativeness
of the family-based discovery GWAS approach, the smaller
P-values of the observed signals justify our subsequent pro-
ceeding.
Secondly, in the case–control GWAS discovery sample, we
performed 10 000 permutations of the case–control status to
see how often we get directionally consistent nominal
minimal one-sided P-values of ≤0.025 as observed for 20
out of the 25 CNVRs detected in the family-based discovery
GWAS sample. In none of the permutations we observed
more than 20 such directionally consistent CNVR ﬁndings;
in two permutation samples, we observed exactly 20 (taken
together resulting in an empirical P-value of 2 × 10
24); the
median was 10 directionally consistent CNVR ﬁndings in
the 10000 permutations.
Thirdly, in order to account for multiple testing in the case–
control GWAS discovery sample, we also performed Bonfer-
roni corrections for the 25 CNVRs tested. Five of the 25
CNVRs followed-up in the case–control GWAS discovery
sample achieved one-sided P-values of ,0.025.
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